Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 14/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1701842 | 1.00 | CTSL (0.60) | CTSLALDH1A1ALOX15CTSKCTSB | |
| SCHEMBL1709151 | 0.87 | ALDH1A1 (0.64) | CTSLALDH1A1ALOX15CTSKCTSB | |
| SCHEMBL1701751 | 0.87 | ALDH1A1 (0.64) | CTSLALDH1A1ALOX15CTSKCTSB | |
| SCHEMBL18257516 | 0.85 | CTSK (0.67) | CTSLCTSKCTSBCTSS | |
| SCHEMBL8276390 | 0.85 | CTSK (0.67) | CTSLCTSKCTSBCTSS | |
| SCHEMBL1796250 | 0.84 | CTSL (0.65) | CTSLCTSKCTSBCASP1CTSS | |
| SCHEMBL2487005 | 0.84 | CTSL (0.65) | CTSLCTSKCTSBCASP1CTSS | |
| SCHEMBL1701581 | 0.84 | CTSL (0.65) | CTSLCTSKCTSBCASP1CTSS | |
| SCHEMBL6139194 | 0.83 | CTSL (0.61) | CTSLCTSKCTSBCASP1CTSS | |
| SCHEMBL27616333 | 0.83 | CTSL (0.61) | CTSLCTSKCTSBCASP1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657058-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-8765745-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765745-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8735441-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8431571-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130053303-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053303-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130041008-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130035297-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-8357683-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053303-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885ALDH1A1 1307/4885ALOX15 1698/4885 |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885ALDH1A1 1307/4885ALOX15 1698/4885 |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885ALDH1A1 1307/4885ALOX15 1698/4885 |
| US-20130041008-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885ALDH1A1 1307/4885ALOX15 1698/4885 |
| US-20070293465-A1 | Compounds for enzyme inhibition | PSME1, PSMB1, PSME3 | CTSL 724/4885ALDH1A1 1307/4885ALOX15 1698/4885 |
| US-20130035297-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885ALDH1A1 1307/4885ALOX15 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.